Neuphoria Therapeutics (NEUP) Deferred Taxes (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Deferred Taxes of -$34794.0 for Q1 2026, up 57.14% year-over-year from -$22141.8 in Q1 2025, and little changed quarter-over-quarter from -$34793.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Deferred Taxes (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Deferred Taxes for 4 consecutive years, with -$34794.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes rose 57.14% year-over-year to -$34794.0; the TTM figure through Mar 2026 stood at -$371004.0 (down 56.81% YoY), while the FY2025 annual figure was -$468427.0, down 236.58% from the prior year.
- Deferred Taxes held at -$34794.0 in Q1 2026 per NEUP's latest filing, from -$34793.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $11597.0 in Q4 2024 and bottomed at -$266624.0 in Q2 2025.
- Historically, Deferred Taxes has averaged -$64725.5 across 4 years, with a median of -$34793.0 in 2023.
- Annual changes were most pronounced in 2024 — Deferred Taxes jumped 133.33% — and 2025, when it sank 666.32%.
- Neuphoria Therapeutics' Deferred Taxes stood at -$34793.0 in 2023, then jumped by 133.33% to $11597.0 in 2024, then slumped by 400.02% to -$34793.0 in 2025, then declined by 0.0% to -$34794.0 in 2026.
- Business Quant data shows NEUP's Deferred Taxes at -$34794.0 in Q1 2026, -$34793.0 in Q4 2025, and -$34793.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | -34,794.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,794.00 |
| Dec 31, 2025 | -34,793.00 |
| Sep 30, 2025 | -34,793.00 |
| Jun 30, 2025 | -266,624.00 |
| Mar 31, 2025 | -81,184.00 |
| Dec 31, 2024 | 11,597.00 |
| Sep 30, 2024 | -132,216.00 |
| Jun 30, 2024 | -34,793.00 |
| Mar 31, 2024 | -34,794.00 |
| Dec 31, 2023 | -34,793.00 |
| Sep 30, 2023 | -34,793.00 |